| Literature DB >> 35459142 |
Lilian N Ruiter1, Boukje A C van Dijk2,3, Annette H Bruggink4, Patricia A H Doornaert5, Marielle E P Philippens5, Remco de Bree6, Carla H van Gils7, Stefan M Willems8,9.
Abstract
BACKGROUND: Recurrences remain an important problem in laryngeal squamous cell carcinoma. Little has been described about histological characteristics of the primary laryngeal tumor that may be associated with recurrences. Identifying risk factors for recurrences might help in adapting treatment or follow-up. Using real-life population-based data, we aimed to identify histological features of the primary tumor associated with recurrences and overall survival.Entities:
Keywords: Histology; Laryngeal neoplasms; Pathology; Recurrence; Squamous cell carcinoma; Survival
Mesh:
Year: 2022 PMID: 35459142 PMCID: PMC9034596 DOI: 10.1186/s12885-022-09533-0
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.638
Fig. 1Flowchart of tumors included in the study. Tumors were excluded when: linking of the databases resulted in no matches or not very reliable matches. It was impossible to screen all records adequately, therefore, of every inclusion year (2010–2014) 50% of the pathology data were extracted of pathology reports. CIS patients were excluded. Only patients with invasive primary laryngeal squamous cell carcinoma with microscopy texts were included. Representativeness of the sample compared to the cohort was analyzed (Supplementary Table 1)
Patient characteristics, locoregional recurrences and death of all patients with laryngeal squamous cell carcinoma (n = 1502) between 2010 and 2014 with at least 2 year follow-up
| Total | Recurrences | Death | ||||||
|---|---|---|---|---|---|---|---|---|
| Characteristics | N | Column | N | Row | N | Row | ||
| 1502 | 100 | 299 | 20 | 555 | 37 | |||
| ‡ | ‡ | |||||||
| M | 1210 | 81 | 252 | 21 | 0.069 | 445 | 37 | 0.776 |
| F | 292 | 19 | 47 | 16 | 110 | 38 | ||
| Median (p25-p75) | 66 (60–74) | 64 (57–72) | 70 (63–78) | |||||
| Mean (±SD) | 67 ± 11 | 64 ± 11 | 70 ± 10 | |||||
| † | † | |||||||
| Glottis | 964 | 64 | 181 | 19 | 0.183 | 266 | 28 | < 0.001 |
| Supraglottis | 509 | 34 | 110 | 22 | 265 | 52 | ||
| Subglottis | 20 | 1 | 4 | 20 | 17 | 85 | ||
| Overlapping / unknowna | 9 | 0.6 | 4 | 44 | 7 | 78 | ||
| † | ~ | |||||||
| T1 | 608 | 41 | 106 | 17 | 0.068 | 151 | 25 | < 0.001 |
| T2 | 392 | 26 | 90 | 23 | 144 | 37 | ||
| T3 | 322 | 21 | 75 | 23 | 167 | 52 | ||
| T4 | 148 | 10 | 23 | 16 | 85 | 57 | ||
| ISb | 12 | 0.8 | 3 | 25 | 0 | 0 | ||
| TXc | 20 | 1.3 | 2 | 10 | 8 | 40 | ||
| ‡ | ‡ | |||||||
| N0 | 1135 | 76 | 214 | 19 | 0.279 | 351 | 31 | < 0.001 |
| N1 | 94 | 6 | 22 | 23 | 51 | 54 | ||
| N2 | 168 | 11 | 43 | 26 | 115 | 68 | ||
| N3 | 9 | 0.6 | 2 | 22 | 6 | 67 | ||
| NXc | 96 | 6 | 18 | 19 | 32 | 33 | ||
| † | † | |||||||
| T1 | 237 | 46 | 41 | 17 | 0.020 | 51 | 22 | < 0.001 |
| T2 | 14 | 3 | 3 | 21 | 3 | 21 | ||
| T3 | 22 | 4 | 2 | 9 | 14 | 64 | ||
| T4 | 83 | 16 | 8 | 10 | 36 | 43 | ||
| TXc | 155 | 30 | 40 | 26 | 42 | 27 | ||
| † | ‡ | |||||||
| N0 | 65 | 13 | 7 | 11 | 0.037 | 19 | 41 | < 0.001 |
| N1 | 20 | 4 | 1 | 5 | 9 | 45 | ||
| N2 | 26 | 5 | 2 | 8 | 19 | 73 | ||
| NXc | 400 | 78 | 84 | 21 | 99 | 25 | ||
| ‡ | ~ | |||||||
| T1/T2N0 Surg. (+RT/syst. therapy) | 318 | 21 | 66 | 21 | < 0.001 | 64 | 20 | < 0.001 |
| T1/T2N0 RT | 512 | 34 | 84 | 16 | 141 | 28 | ||
| T1/T2N+ RT | 71 | 5 | 25 | 35 | 42 | 59 | ||
| T3/T4N0/N+ Surg. (+RT/syst. therapy) | 120 | 8 | 16 | 13 | 64 | 53 | ||
| T3/T4N0/N+ RT+/− syst. therapy) | 318 | 21 | 79 | 25 | 152 | 48 | ||
| Other | 163 | 11 | 29 | 18 | 92 | 56 | ||
a Overlapping or unknown: ICD-O-3: C32.8 or C32.9
b IS: tumors initially clinically assessed as CIS (Carcinoma In Situ), but based on PA-tissue assessed as invasive carcinoma
c TX/NX: T/N stage cannot be assessed
d Only surgery patients (n = 511)
e Only patients with PA-material of lymph nodes (n = 511)
† Fisher’s exact test
‡ Chi square test
~ Monte Carlo simulation based on 103 sampled tables
Histological tumor characteristics, locoregional recurrences and death of all patients with laryngeal squamous cell carcinoma (n = 1502)
| Histological features | Total | Recurrences | Death | |||||
|---|---|---|---|---|---|---|---|---|
| N | Column | N | Row | N | Row | |||
| † | † | |||||||
| No | 1448 | 96 | 291 | 20 | 0.79 | 523 | 36 | 0.001 |
| Yes | 51 | 3 | 8 | 16 | 31 | 61 | ||
| Unclear / not evaluable | 3 | 0.2 | 0 | 0 | 1 | 33 | ||
| † | † | |||||||
| No | 1459 | 97 | 290 | 20 | 0.74 | 532 | 37 | 0.036 |
| Yes | 39 | 3 | 9 | 23 | 22 | 56 | ||
| Unclear / not evaluable | 4 | 0.3 | 0 | 0 | 1 | 25 | ||
| ‡ | ‡ | |||||||
| Cohesive growth | 830 | 55 | 165 | 20 | 0.79 | 302 | 36 | 0.399 |
| Non-cohesive growth | 329 | 22 | 62 | 19 | 116 | 35 | ||
| Unclear / not evaluable | 20 | 1 | 6 | 30 | 5 | 25 | ||
| Not determined | 323 | 22 | 66 | 20 | 132 | 41 | ||
| ‡ | ‡ | |||||||
| No adverse characteristics | 798 | 53 | 161 | 20 | 0.85 | 283 | 36 | 0.027 |
| One adverse characteristics | 318 | 21 | 58 | 18 | 111 | 35 | ||
| Two/three adverse characteristics | 41 | 3 | 8 | 20 | 23 | 56 | ||
| One or more characteristics unknown | 345 | 23 | 72 | 21 | 138 | 40 | ||
| ‡ | ‡ | |||||||
| No | 212 | 14 | 44 | 21 | 0.88 | 81 | 38 | 0.664 |
| Yes | 867 | 58 | 174 | 20 | 312 | 36 | ||
| Unclear / not evaluable | 26 | 2 | 5 | 19 | 11 | 42 | ||
| Not determined | 397 | 26 | 76 | 19 | 151 | 38 | ||
| ‡ | ‡ | |||||||
Well differentiated (grade 1) | 128 | 9 | 23 | 18 | 0.95 | 37 | 29 | < 0.001 |
Moderately differentiated (grade 2) | 595 | 40 | 118 | 20 | 220 | 37 | ||
Poorly differentiated (grade 3) | 214 | 14 | 43 | 20 | 110 | 51 | ||
| Unclear / not evaluable | 4 | 0.3 | 0 | 0 | 2 | 50 | ||
| Not determined | 561 | 37 | 115 | 21 | 186 | 33 | ||
Fig. 2Multivariable analysis of histological characteristics of the primary tumor corrected for age, gender, sublocalisation and stage/treatment for locoregional recurrence and death n = 1502